Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Immunology/Allergy

Allergy

24

Pipeline Programs↗

45

Active Trials↗

26

Companies Involved↗

Allergy is an emerging landscape with 24 programs across 26 companies. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

47/100

Mech. Concentration

50/100

Completion Rate

85/100

Attrition Rate

11/100

Pipeline

Programs by Phase

Preclinical18

Olopatadine

Novartis

Allergen Specific Immunotherapy

University of Zurich

Beclomethasone

Chiesi Farmaceutici S.p.A.

BAY987517

Bayer

SPF Control

Bayer

Phase 11

Linvoseltamab

Regeneron

Phase 24

Peanut Immunotherapy

University of North Carolina, Chapel Hill

Peanut OIT

University of North Carolina, Chapel Hill

PVX-108

Aravax Pty Ltd

Dupilumab

Azienda U.S.L. 1 di Massa e Carrara

Phase 31

Measles-Mumps-Rubella Vaccine

Liaoning Chengda Biotechnology CO., LTD

Approved

No programs

Analysis

Modality Breakdown

81%

Small molecule

13 of 16 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 100% of 24 pipeline programs.

Analysis

Trial Status

208

clinical trials

Completed127 · 61%

Recruiting28 · 13%

Terminated14 · 7%

Unknown status12 · 6%

Withdrawn9 · 4%

Not yet recruiting8 · 4%

Other10 · 5%

Clinical Trials

Trial Activity

208 trials

Identification and Quantitation of Human B Regulatory Cells Via Flow Cytometry and Their Potential Role as a Treatment Efficacy Biomarker in Allergen-specific Immunotherapy

Recruiting·HHull University Teaching Hospitals NHS Trust·N/A·NCT06876506·80 enrolled

Efficacy of Tezepelumab in Peanut Oral Immunotherapy: a Double-Blind, Randomized, Placebo-Controlled Trial

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT07015996·62 enrolled

Natural History and Genetics of Food Allergy and Related Conditions

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT02504853·1,800 enrolled

A 52-week Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy and Safety of Remibrutinib (LOU064) in Adult and Adolescent Participants With IgE-mediated Food Allergy

Recruiting· Novartis logo

Novartis·Phase 3·NCT07768371·576 enrolled

Study of Oral Food Challenge Biomarkers (CoFAR-15)

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT07279467·500 enrolled

Evaluation of the Hypoallergenicity of a New Formula Based on Hydrolyzed Rice Proteins in Children With IgE-mediated Cow's Milk Allergy

Recruiting·HHealth and Happiness Research Limited·Preclinical·NCT07197814·29 enrolled

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Recruiting·MMassachusetts General Hospital·Phase 2·NCT06406114·300 enrolled

Investigating Clinical Features, Natural Course and Pathophysiology of Non-Immunoglobulin E-mediated Food Allergies in the Pediatric Age

Recruiting·FFederico II University·N/A·NCT04462978·150 enrolled

Prospective Study to Identify Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in Patients With Elevated Total Serum IgE Levels and Atopic Dermatitis

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03835767·200 enrolled

The Effect of Watching Cartoons and Using a Stress Ball on Fear, Anxiety, Pain, and Satisfaction During Allergy Testing in Children

Recruiting·TTarsus University·Preclinical·NCT07750236·90 enrolled

Treatment of Ocular Surface Inflammations With 1% Cyclosporine (Ikervis) Eye Drops

Recruiting·SSemmelweis University·N/A·NCT07732855·50 enrolled

Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Recruiting·RRAPT Therapeutics, Inc.·Phase 2·NCT07220811·100 enrolled

Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg

Recruiting·UUniversity of Rochester·Preclinical·NCT06260956·500 enrolled

Determination of Hypoallergenicity of an Extensively Hydrolyzed Infant Formula in Infants and Children With Cow's Milk Allergy

Recruiting·—·Preclinical·NCT06456541·96 enrolled

Safety of MOON101 for the Treatment of Peanut Allergy

Recruiting·MMoonlight Therapeutics, Inc.·Phase 1·NCT07580898·40 enrolled

Page 1 of 14

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)